Summit's ivonescimab cuts death risk 24% (HR 0.76) in Western NSCLC patients at the 2-year HARMONi mark, but median survival figures remain undisclosed.
Summit Therapeutics unveiled additional follow-up data on its experimental cancer drug ivonescimab, and how its benefit compares between Asian and Western patients. But key context …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Ivonescimab Plus Chemotherapy Shows Consistent, Favorable Overall Survival Results in Western and Asian Patients in Updated…
Summit Therapeutics shares updated Phase 3 data, revealing improving overall survival trends for lung cancer therapy ivonescimab.
A lung cancer drug developed in China was a highlight of ASCO but doctors want to see follow-up in a more diverse population.
Ivonescimab reduced the risk of death by one-third compared to chemotherapy in a China-based study that’s seen as an important…
Aiming to bolster ivonescimab’s case ahead of a key FDA decision, Summit Therapeutics has provided
Ivonescimab with Chemotherapy Demonstrated a Statistically Significant Overall Survival Benefit Compared to Tislelizumab Plus…
Ivonescimab Plus Chemotherapy Shows Consistent, Favorable Overall Survival Results in Western and Asian Patients in Updated Analysis from Global Phase III HARMONi Study
Summit Therapeutics Says Extended Follow-Up Reveals Stronger Survival Advantages with lead Cancer Drug -
